Interactions between neuroleptics and CYP2C6 in rat liver - In vitro and ex vivo study

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 872-877

  Haduch, Anna ^a   Ogórka, Tomasz ^a   Boksa, Jan ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chronic treatment; CYP2C6; Haloperidol; In vitro study; Liver microsomes; Phenothiazines; Rat; Risperidone; Sertindole; Warfarin 7 hydroxylation

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERAZINE; PROMAZINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33645695378     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RI: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 1995, 25, 261-270.
2. Chen H, Howald WN, Juchau MR: Biosynthesis of alltrans-retinoic acid from all-trans-retinol: catalysis of alltrans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos, 2000, 28, 315-322.
3. Daniel WA: Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27, 65-73.
4. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
5. Daniel WA, Haduch A, Wójcikowski J: Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo - possible involvement of different mechanisms. Eur Neuropsychopharmacol, 2005, 15, 103-110.
6. Daniel W, Syrek M, Janczar L, Boksa J: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats - a comparison with the pharmacokinetics of imipramine. Pol J Pharmacol, 1995, 47, 127-136.
7. Eagling VA, Tja IF, Back DJ: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol, 1998, 45, 107-114.
8. Gerbal-Chaolin S, Pascussi J-M, Pichard-Garcia L, Daujat M, Waechter F, Fabre J-M, Carrére N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos, 2001, 29, 242-251.
9. Gottlieb RA, Huang C, Paromov V, Taukada Y, Wentworth P: Role of cytochrome P450 in myocardial reperfusion injury. Cardiovasc J S Afr, 2004, 4, SuppI 1, S1.
10. Hermodson MA, Barker WM, Link KP: Studies on the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J Med Chem, 1971, 14, 167-169.
11. Jansing RL, Chao ES, Kaminsky LS: Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol Pharmacol, 1992, 41, 209-215.
12. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther, 1997, 73, 67-74.
13. Kobayashi K, Urashima K, Shimada N, Chiba K: Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol, 2002, 63, 889-896.
14. Kobayashi K, Urashima K, Shimada N, Chiba K: Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab Dispos, 2003, 31, 833-836.
15. Lang D, Bocker R: Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B, 1995, 672, 305-309.
16. Lewis DFV: Guide to Cytochromes P450. Structure and Function. In: Taylor & Francis, London and New York, 2001, p. 83.
17. Newton DJ, Wang RW, Lu AYH: Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos, 1995, 23, 154-158.
18. Shaw PM, Adesnik M, Weiss MC, Corcos L: The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486. Mol Pharmacol, 1993, 44, 775-783.
19. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS et al.: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos, 2002, 30, 1102-1107.
20. Shin JG, Soukhova N, Flockhart DA: Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos, 1999, 27, 1078-1084.
21. Wong SL, Cao G, Mack RJ, Granneman GR: Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther, 1997, 62, 157-164.
22. Wójcikowski J, Daniel WA: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol, 2000, 52, 449-457.
23. Wójcikowski J, Daniel WA: Thioridazine fluoxetine interaction at the level of the distribution process in vitro. Pol J Pharmacol, 2002, 54, 647-654.
24. Yamazaki H, Komatsu T, Takemoto T, Saeki M, Minami Y, Kawaguchi Y, Shimada N et al.: Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos, 2001, 29, 427-434.